ClinicalTrials.gg
CompletedNCT02776215Updated Mar 21, 2024

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

A Phase 1 interventional study of tasimelteon in Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder and Autism Spectrum Disorder, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Enrollment
40th of 54
24 · median 50
Started
2016
with 2 others
Phase 1
6 of 69
2 open now
Registered
33rd of 69
by date
Lead sponsor
6 of 69
Vanda Pharmaceuticals

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 40th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1, and was the 33rd registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.

Read the detailed description

This study is an open-label, single dose, non-controlled study to evaluate the PK and safety of tasimelteon in children and adolescents from 3 years to less than 18 years of age who were legally blind and met the diagnostic criteria for CRSWD Non-24 per DSM-V or who were diagnosed with a Neurodevelopmental Disorder (like ASD and SMS) and had a nighttime sleep complaint.

03

Conditions studied

  • Circadian Rhythm Sleep Disorders
  • Non-24 Hour Sleep-Wake Disorder
  • Autism Spectrum Disorder
  • Smith-Magenis Syndrome
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females 3 to \<18 years of age who are legally blind [defined as having a visual acuity of 20/200 or less in the better-seeing eye with best conventional correction (glasses or contact lenses) and/or a visual field of 20 degrees or less in the better-seeing eye], males or females 3 to \<18 years of age with SMS and with a nighttime sleep complaint and males or females 3 to \<18 years of age with ASD and with a nighttime sleep complaint;
  2. Weigh at least 10 kg;

3 Diagnosis of SMS determined by a prior positive genetic test result as indicated by parent/guardian; Diagnosis of ASD as indicated by parent/guardian; or a diagnosis of Non-24 as determined by diagnostic criteria for the Circadian rhythm sleep-wake disorder, Non-24-hour sleep-wake hour type:

  1. A persistent or recurrent pattern of sleep disruption that is primarily due to an alteration of the circadian system or to a misalignment between the endogenous circadian rhythm and the sleep-wake schedule required by an individual's physical environment or social or professional schedule;
  2. The sleep disruption leads to excessive sleepiness or insomnia, or both;
  3. The sleep disturbance causes distress or impairment in social, occupational, and other important areas of functioning.

Exclusion criteria

Exclusion Criteria:

  1. For blind subjects only: Subjects who have a probable diagnosis of a current sleep disorder other than Non-24-Hour Sleep-Wake Disorder that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;
  2. For blind subjects only: History (within the 12 months prior to screening) of psychiatric disorders including ADHD, Neurodisabilities, Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder, that is not being successfully treated or has not been resolved and that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
  3. History of intolerance and/or to melatonin or melatonin agonists;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Pharmacokinetic Dosing

    Single-dose pharmacokinetics of tasimelteon

    Drug: tasimelteon

Interventions

  • Melatonin receptor agonist

    Also known as: Hetlioz

06

What researchers measure

Primary outcomes

  1. Area under the curver (AUC) of tasimelteon and its metabolites

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose

  2. Maximum concetration (Cmax) of tasimelteon and its metabolites

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose

  3. Steady-state concentration (Css) of tasimelteon and its metabolites

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose

  4. Half-life of tasimelteon and its metabolites

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose

  5. Trough concentration (Ctrough) of tasimelteon and its metabolites

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose,1 hour post dose, 2 hours post dose, 4 hours post dose

  6. Safety and tolerability of tasimelteon as measured by spontaneous reporting of adverse events (AEs)

    Time frame: Day 1

  7. Safety and tolerability of tasimelteon as measured by Pediatric Adverse Event Reporting System (PAERS)

    Time frame: Day 1

07

Study locations

1 site
  • Parexel Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Dec 2017, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2016
First posted
May 18, 2016
StartActual
Oct 4, 2016
Primary completionActual
Dec 20, 2017
CompletionActual
Dec 20, 2017
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02776215
Responsible party
Sponsor
First posted
May 18, 2016
Start date
Oct 4, 2016
Primary completion
Dec 20, 2017
Completion
Dec 20, 2017
Last update
Mar 21, 2024

Study contacts

Vanda Pharmaceuticals
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion